e16015 Background: Androgen deprivation therapy (ADT) improves disease-free survival but disease progression is related, in part, to ineffective castration. The free hormone hypothesis states that the biological activity of steroid hormones is affected by its unbound (free) rather than its protein-bound concentration. Serum total testosterone (T) concentrations predominantly reflect the T bound to plasma proteins and do not accurately predict prostatic levels of T. Methods: In a Phase II study (G200705), men with advanced prostate cancer (n=159) were randomized to receive 1000 mg or 2000 mg GTx-758 daily or leuprolide as their initial ADT. Serum total T (mass spectrometry), free T (equilibrium dialysis), SHBG and PSA concentrations were measured. A second Phase II study (G20007) was performed in men (n=9) with CRPC who then received GTx-758 2000 mg daily. Results: Although both treatments reduced serum total T levels to < 50 ng/dL, leuprolide decreased them to a greater extent. However, GTx-758 caused greater reductions in serum PSA, suggesting that total T concentrations did not accurately reflect the suppression of androgen activity. Both dosages of GTx-758 reduced free T levels to a greater extent (mean of 0.7 and 0.4 pg/ml at day 60, and 0.4 and 0.4 pg/ml on day 90, respectively) than leuprolide (mean of 1.4 pg/ml on day 60 and 1.4 pg/ml on day 90; p values <0.03). Similar clinical results were observed in CRPC patients where GTx-758 daily resulted in a 71% decrease in %free T and clinically relevant PSA reductions in men maintained on ADT with LHRH agonists. As a result of adverse events at higher doses of GTx-758, the trial was stopped early. Conclusions: The ERα agonist, GTx-758, reduced the biologically active form of T, free T, to significantly lower levels than leuprolide. Reductions in PSA appeared to be more highly associated with changes in free T. These data provide compelling evidence to support the free hormone hypothesis and suggest that serum free T concentrations would provide a better measure of therapeutic efficacy in ADT than total T. A Phase II clinical trial utilizing lower doses of GTx-758 (G200712) is currently being performed. Clinical trial information: NCT01326312.
Read full abstract